CoChat
Sign Up
Cited by 235Glioma Diagnosis and TreatmentCancer Genomics and DiagnosticsCancer-related Molecular Pathways

Genetic pathways to glioblastomas

Ohgaki, Hiroko·2005·Neuropathology
DOI 10.1111/j.1440-1789.2004.00600.x
Open this paper in CoChat — free account

Abstract

Glioblastomas, the most frequent and malignant human brain tumors, may develop de novo (primary glioblastoma) or by progression from low-grade or anaplastic astrocytoma (secondary glioblastoma). These glioblastoma subtypes constitute distinct disease entities that affect patients of different ages and develop through different genetic pathways. Our recent population-based study in the Canton of Zürich, Switzerland, shows that primary glioblastomas develop in older patients (mean age, 62 years) and typically show LOH on chromosome 10q (69%) and other genetic alterations (EGFR amplification, TP53 mutations, p16INK4a deletion, and PTEN mutations) at frequencies of 24-34%. Secondary glioblastomas develop in younger patients (mean, 45 years) and frequently show TP53 mutations (65%) and LOH 10q (63%). Common to both primary and secondary glioblastoma is LOH on 10q, distal to the PTEN locus; a putative suppressor gene at 10q25-qter may be responsible for the glioblastoma phenotype. Of the TP53 point mutations in secondary glioblastomas, 57% were located in hotspot codons 248 and 273, while in primary glioblastomas, mutations were more widely distributed. Furthermore, G:C-->A:T mutations at CpG sites were more frequent in secondary than in primary glioblastomas (56% vs 30%). These data suggest that the TP53 mutations in these glioblastoma subtypes arise through different mechanisms. There is evidence that G:C-->A:T transition mutations at CpG sites in the TP53 gene are significantly more frequent in low-grade astrocytomas with promoter methylation of the O6-methylguanine-DNA methyltransferase (MGMT) gene than in those without methylation. This suggests that, in addition to deamination of 5-methylcytosine (the best known mechanism of formation of G:C-->A:T transitions at CpG sites), involvement of alkylating agents that produce O6-methylguanine or related adducts recognized by MGMT cannot be excluded in the pathway leading to secondary glioblastomas.

Integrity signals

Registry

Crossref · 10.1111/j.1440-1789.2004.00600.x

Cites

64 of 64 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • TP53 mutations have been reported both in primary and secondary grade glioblastoma lesions (30% and 65%, respectively).

    “TP53 mutations have been reported both in primary and secondary grade lesions (30% and 65%, respectively) [86,87].”

    From The p53 Pathway in Glioblastoma (2018) · cites this paper as [86]

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Related

Authors
Ohgaki, H.
Affiliations
Centre international de recherche sur le cancer (FR)
Corresponding author
Ohgaki, Hiroko
Venue
Neuropathology
Publisher
Wiley
Published
2005-02-28
Volume
25
Issue
1
Pages
1-7
ISSN
  • 0919-6544 (ISSN-L)
  • 1440-1789
DOI
10.1111/j.1440-1789.2004.00600.x
OpenAlex
W2097876071
Cited by
235
References
64
Citations by year
2026: 4 · 2025: 2 · 2024: 6 · 2023: 5 · 2022: 3 · 2021: 4 · 2020: 8 · 2019: 8 · 2018: 7 · 2017: 6 · 2016: 14 · 2015: 8 · 2014: 12 · 2013: 11 · 2012: 11
FWCI
3.08
Type
journal article
Language
en
Open access
closed
Licence
onlinelibrary.wiley.com/termsAndConditions#vor (vor)
Locations
  • Neuropathology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Genetics › Glioma Diagnosis and Treatment
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
  • Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
Keywords
glioblastoma, primary glioblastoma, secondary glioblastoma, low-grade astrocytoma, anaplastic astrocytoma, tumor progression, TP53 mutation, promoter methylation, MGMT, alkylating agents, EGFR amplification, PTEN mutation, suppressor genes, gene pathways
MeSH terms
Age Factors, Brain Neoplasms, Glioblastoma, Humans, Middle Aged

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review